Tags

Type your tag names separated by a space and hit enter

No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial.
Eur J Prev Cardiol 2014; 21(11):1429-36EJ

Abstract

BACKGROUND

Persistent inflammation plays a role in the pathogenesis of atherosclerosis. n-3 Fatty acids may have anti-inflammatory effects. This study examined the effect of plant-derived alpha-linolenic acid (ALA) and marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on high-sensitivity C-reactive protein (hsCRP), a systemic marker of (low-grade) inflammation.

DESIGN/METHODS

A supplementary study in the Alpha Omega Trial: a multicenter, double-blind, randomized, placebo-controlled trial of low-dose n-3 fatty acids. Patients were enrolled from 2002 to 2006 and followed for 40 months. A total of 2425 patients, aged 60-80 years (79% men), with a history of myocardial infarction, were randomly assigned to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months.

RESULTS

Patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active treatment groups. In the placebo group, the geometric mean hsCRP (95% confidence interval (CI)) was 1.84 mg/l (95% CI: +1.70 to +2.00) at baseline and 1.98 mg/l (95% CI: 1.82 to 2.15) after 40 months (p < 0.0001). hsCRP levels were not affected by ALA (-5% versus placebo; 95% CI: -14% to +6%, p = 0.37), EPA-DHA (-8% versus placebo; 95% CI: -17% to +2%, p = 0.13), or EPA-DHA plus ALA (-3% versus placebo; 95% CI: -12% to +8%, p = 0.62).

CONCLUSIONS

Long-term supplementation with modest amounts of EPA-DHA, whether or not in combination with ALA, did not affect hsCRP levels in patients with a history of myocardial infarction.

TRIAL REGISTRATION CLINICALTRIALSGOV NUMBER

NCT00127452.

Authors+Show Affiliations

Department of Internal Medicine and Nephrology, Jeroen Bosch Hospital, Den Bosch, The Netherlands ellen.hoogeveen@planet.nl.Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.Division of Human Nutrition, Wageningen University, Wageningen, The Netherlands.Department of Psychiatry, Leiden University Medical Center, Leiden, The Netherlands.

Pub Type(s)

Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

23774275

Citation

Hoogeveen, Ellen K., et al. "No Effect of N-3 Fatty Acids On High-sensitivity C-reactive Protein After Myocardial Infarction: the Alpha Omega Trial." European Journal of Preventive Cardiology, vol. 21, no. 11, 2014, pp. 1429-36.
Hoogeveen EK, Geleijnse JM, Kromhout D, et al. No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. Eur J Prev Cardiol. 2014;21(11):1429-36.
Hoogeveen, E. K., Geleijnse, J. M., Kromhout, D., & Giltay, E. J. (2014). No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. European Journal of Preventive Cardiology, 21(11), pp. 1429-36. doi:10.1177/2047487313494295.
Hoogeveen EK, et al. No Effect of N-3 Fatty Acids On High-sensitivity C-reactive Protein After Myocardial Infarction: the Alpha Omega Trial. Eur J Prev Cardiol. 2014;21(11):1429-36. PubMed PMID: 23774275.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - No effect of n-3 fatty acids on high-sensitivity C-reactive protein after myocardial infarction: the Alpha Omega Trial. AU - Hoogeveen,Ellen K, AU - Geleijnse,Johanna M, AU - Kromhout,Daan, AU - Giltay,Erik J, Y1 - 2013/06/17/ PY - 2013/6/19/entrez PY - 2013/6/19/pubmed PY - 2015/6/24/medline KW - alpha-linolenic acid KW - docosahexaenoic acid KW - eicosapentaenoic acid KW - high-sensitivity C-reactive protein KW - n-3 Fatty acids KW - randomized double-blind placebo-controlled trial SP - 1429 EP - 36 JF - European journal of preventive cardiology JO - Eur J Prev Cardiol VL - 21 IS - 11 N2 - BACKGROUND: Persistent inflammation plays a role in the pathogenesis of atherosclerosis. n-3 Fatty acids may have anti-inflammatory effects. This study examined the effect of plant-derived alpha-linolenic acid (ALA) and marine n-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) on high-sensitivity C-reactive protein (hsCRP), a systemic marker of (low-grade) inflammation. DESIGN/METHODS: A supplementary study in the Alpha Omega Trial: a multicenter, double-blind, randomized, placebo-controlled trial of low-dose n-3 fatty acids. Patients were enrolled from 2002 to 2006 and followed for 40 months. A total of 2425 patients, aged 60-80 years (79% men), with a history of myocardial infarction, were randomly assigned to margarines supplemented with a targeted additional intake of 400 mg/day EPA and DHA, 2 g/day ALA, EPA-DHA plus ALA, or placebo for 40 months. RESULTS: Patients consumed on average 19.8 g margarine/day, providing an additional amount of 238 mg/day EPA with 158 mg/day DHA, 1.98 g/day ALA, or both, in the active treatment groups. In the placebo group, the geometric mean hsCRP (95% confidence interval (CI)) was 1.84 mg/l (95% CI: +1.70 to +2.00) at baseline and 1.98 mg/l (95% CI: 1.82 to 2.15) after 40 months (p < 0.0001). hsCRP levels were not affected by ALA (-5% versus placebo; 95% CI: -14% to +6%, p = 0.37), EPA-DHA (-8% versus placebo; 95% CI: -17% to +2%, p = 0.13), or EPA-DHA plus ALA (-3% versus placebo; 95% CI: -12% to +8%, p = 0.62). CONCLUSIONS: Long-term supplementation with modest amounts of EPA-DHA, whether or not in combination with ALA, did not affect hsCRP levels in patients with a history of myocardial infarction. TRIAL REGISTRATION CLINICALTRIALSGOV NUMBER: NCT00127452. SN - 2047-4881 UR - https://www.unboundmedicine.com/medline/citation/23774275/No_effect_of_n_3_fatty_acids_on_high_sensitivity_C_reactive_protein_after_myocardial_infarction:_the_Alpha_Omega_Trial_ L2 - http://journals.sagepub.com/doi/full/10.1177/2047487313494295?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub=pubmed DB - PRIME DP - Unbound Medicine ER -